Receptors providing targeted costimulation for adoptive cell therapy
US12187778B2 · kind B2 · utility
0Cited by
34References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 30, 2022 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Aug 30, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.